Ambev has experienced a wave of positive financial updates, highlighted by Barclays increasing its price target from $2.50 to $3.00 and an upward shift in revenue growth assumptions to 5.13%. The company anticipates a sales growth of 13.3% this year and EPS growth of 2.8%, alongside approved dividends of R$0.4612 per share. These developments, along with a Zacks Rank of #2 (Buy), reflect strong investor confidence and positions Ambev favorably ahead of its board meeting scheduled for February 11, 2026.
“Ambev · fair value estimate updated · R$13.98 · R$14.81”
“Ambev · discount rate moved · 18.16% · 18.09%”
“Ambev · revenue growth assumptions shifted · 4.60% · 5.13%”
“Barclays · lifted Ambev price target · US$2.50 · US$3”
“Ambev · scheduled board meeting · February 11, 2026 · true”
“Ambev · dividend distribution approved · R$0.4612 · per share”
“Ambev · shares set to trade ex interest · December 19, 2025 · true”
“Ambev (ABEV) · is on the list of · recommended stocks · true”
“Ambev · has an EPS growth rate · 1.3% · historical”
“Ambev · is expected to grow · EPS · 2.8% this year”
“Ambev · has an asset utilization ratio · 0.62 · current”
“Ambev · is expected to grow · sales · 13.3% this year”